SeekingAlpha · Sep 10, 2026
ResMed: A Significant Upside Despite The Perceived Risk
ResMed has been de-rated from 30x to under 21x earnings despite 17% EPS growth, driven by narrative rather than fundamentals. See why RMD stock is a Buy.
NYSE · RMD
ResMed Inc.
Healthcare · Medical - Instruments & Supplies
$229.44
Up+$6.45 (+2.89%)
Updated Sep 16, 2026, 9:17 AM
SID Score
6.3/10
Composite research score
Smart Money
62/100
Neutral
- Market cap
- 36.98B
- P/E ratio
- 25.71
- Dividend yield
- 0.99%
- 52-week range
- $180.27 – $277.67
- Volume
- 1.64M
- Avg. volume
- 1.04M
Price performance
RMD price history
1M range · 20 trading sessions · Daily adjusted prices
RMD closed at $229.44 after 20 trading sessions, up 4.30% for the selected period.
- Last close
- $229.44
- Period change
- +4.30%
- Period low
- $218.27
- Period high
- $240.33
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $226.36 | $234.33 | $225.115 | $229.44 | 1.64M |
| Sep 14, 2026 | $221.04 | $225.82 | $220.94 | $222.99 | 989.01K |
| Sep 11, 2026 | $220.44 | $221.29 | $215.97 | $218.27 | 912.33K |
| Sep 10, 2026 | $217.93 | $221.253 | $215.80 | $219.58 | 923.14K |
| Sep 9, 2026 | $220.845 | $220.845 | $217.00 | $219.95 | 1.2M |
| Sep 8, 2026 | $226.22 | $226.665 | $220.445 | $221.05 | 1.96M |
| Sep 4, 2026 | $225.91 | $228.49 | $225.12 | $228.35 | 843.84K |
| Sep 3, 2026 | $231.20 | $233.045 | $227.265 | $229.19 | 1.48M |
| Sep 2, 2026 | $234.73 | $237.21 | $230.78 | $230.87 | 1.16M |
| Sep 1, 2026 | $239.90 | $242.40 | $230.175 | $231.36 | 987.08K |
| Aug 31, 2026 | $237.97 | $241.71 | $236.16 | $240.10 | 1.72M |
| Aug 28, 2026 | $236.64 | $241.06 | $235.01 | $240.33 | 1.39M |
| Aug 27, 2026 | $233.06 | $237.94 | $232.29 | $235.76 | 1.59M |
| Aug 26, 2026 | $233.66 | $237.76 | $232.10 | $235.69 | 1.54M |
| Aug 25, 2026 | $232.22 | $238.37 | $231.885 | $236.59 | 1.76M |
| Aug 24, 2026 | $231.00 | $233.23 | $228.87 | $232.45 | 1.11M |
| Aug 21, 2026 | $229.44 | $234.14 | $228.5386 | $231.52 | 1.73M |
| Aug 20, 2026 | $229.03 | $232.99 | $228.38 | $228.44 | 1.29M |
| Aug 19, 2026 | $221.00 | $231.04 | $220.44 | $230.65 | 1.21M |
| Aug 18, 2026 | $221.00 | $223.47 | $219.97 | $219.98 | 1.3M |
Latest RMD news
The latest Smart Investors Daily articles mentioning RMD.
Stock researchCompany · Overview
RMD research
Overview
Company profile and research snapshot.
Company profile
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $296.00
- Implied upside
- —
- Analysts
- 25
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 15, 2026 | RBC Capital | Outperform | — |
| Aug 31, 2026 | Keybanc | Overweight | — |
| Aug 19, 2026 | Rothschild & Co | Neutral | — |
| Aug 7, 2026 | Wells Fargo | Equal-Weight | — |
| Aug 7, 2026 | Keybanc | Overweight | — |
News briefing
No generated briefing is available yet.
ChartMill · Sep 3, 2026
ResMed (NYSE:RMD): A Quality Dividend Play Built on Sustainable Payouts
ResMed (RMD) earns a high ChartMill Dividend Rating with a sustainable 1.25% yield, 22.95% payout ratio, and top-tier profitability and health scores.
Benzinga · Sep 1, 2026
ResMed Announces $450M Accelerated Share Repurchase Agreement With Citibank
https://www.sec.gov/ix?doc=/Archives/edgar/data/0000943819/000119312526378487/d530283d8k.htm
Yahoo · Sep 1, 2026
Frazier Healthcare Partners Completes Acquisition of MatrixCare, Appoints Jonathan Lujan as Chief Executive Officer
SEATTLE, September 01, 2026--Frazier Healthcare Partners ("Frazier"), a private equity firm focused exclusively on the healthcare industry, today announced the closing of its acquisition of MatrixCare (the "Company") from Resmed (NYSE & ASX: RMD).
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
